Cargando…
Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy
In recent years, the incidence of cancer has been increasing worldwide. Conventional cancer treatments include surgery, chemotherapy, and radiation, which mostly kill tumor cells at the expense of normal and immune cells. Although immunotherapy is an accurate, rapid, efficient tumor immune treatment...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016614/ http://dx.doi.org/10.1177/10732748221088825 |
_version_ | 1784688565265891328 |
---|---|
author | Peng, Zheng Lv, Xiaolan Huang, Shigao |
author_facet | Peng, Zheng Lv, Xiaolan Huang, Shigao |
author_sort | Peng, Zheng |
collection | PubMed |
description | In recent years, the incidence of cancer has been increasing worldwide. Conventional cancer treatments include surgery, chemotherapy, and radiation, which mostly kill tumor cells at the expense of normal and immune cells. Although immunotherapy is an accurate, rapid, efficient tumor immune treatment, it causes serious adverse reactions, such as cytokine release syndrome (CRS) and neurotoxicity. Therefore, there is an urgent need to develop an effective and nontoxic procedure for immunotherapy. The clinical combination of phototherapy and immunoadjuvant therapy can induce immunogenic cell death and enhance antigen presentation synergy. It also causes a systemic antitumor immune response to manage residual tumors and distant metastases. Photoimmunotherapy (PIT) is a tumor treatment combining phototherapy with immunotherapy based on injecting a conjugate photosensitizer (IR700) and a monoclonal antibody (mAb) to target an expressed antigen on the tumor surface. This combination can enhance the immune response ability, thus having a good effect on the treatment of residual tumor and metastatic cancer. In this review, we summarize the recent progress in photoimmunotherapy, including photoimmunoconjugate (PIC), the activation mechanism of immunogenic cell death (ICD), the combination therapy model, opportunities and prospects. Specifically, we aim to provide a promising clinical therapy for solid tumor clinical transformation. |
format | Online Article Text |
id | pubmed-9016614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-90166142022-04-20 Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy Peng, Zheng Lv, Xiaolan Huang, Shigao Cancer Control Precise medicine in cancer control: from immunotherapy to artificial intelligence - Review In recent years, the incidence of cancer has been increasing worldwide. Conventional cancer treatments include surgery, chemotherapy, and radiation, which mostly kill tumor cells at the expense of normal and immune cells. Although immunotherapy is an accurate, rapid, efficient tumor immune treatment, it causes serious adverse reactions, such as cytokine release syndrome (CRS) and neurotoxicity. Therefore, there is an urgent need to develop an effective and nontoxic procedure for immunotherapy. The clinical combination of phototherapy and immunoadjuvant therapy can induce immunogenic cell death and enhance antigen presentation synergy. It also causes a systemic antitumor immune response to manage residual tumors and distant metastases. Photoimmunotherapy (PIT) is a tumor treatment combining phototherapy with immunotherapy based on injecting a conjugate photosensitizer (IR700) and a monoclonal antibody (mAb) to target an expressed antigen on the tumor surface. This combination can enhance the immune response ability, thus having a good effect on the treatment of residual tumor and metastatic cancer. In this review, we summarize the recent progress in photoimmunotherapy, including photoimmunoconjugate (PIC), the activation mechanism of immunogenic cell death (ICD), the combination therapy model, opportunities and prospects. Specifically, we aim to provide a promising clinical therapy for solid tumor clinical transformation. SAGE Publications 2022-04-13 /pmc/articles/PMC9016614/ http://dx.doi.org/10.1177/10732748221088825 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Precise medicine in cancer control: from immunotherapy to artificial intelligence - Review Peng, Zheng Lv, Xiaolan Huang, Shigao Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy |
title | Photoimmunotherapy: A New Paradigm in Solid Tumor
Immunotherapy |
title_full | Photoimmunotherapy: A New Paradigm in Solid Tumor
Immunotherapy |
title_fullStr | Photoimmunotherapy: A New Paradigm in Solid Tumor
Immunotherapy |
title_full_unstemmed | Photoimmunotherapy: A New Paradigm in Solid Tumor
Immunotherapy |
title_short | Photoimmunotherapy: A New Paradigm in Solid Tumor
Immunotherapy |
title_sort | photoimmunotherapy: a new paradigm in solid tumor
immunotherapy |
topic | Precise medicine in cancer control: from immunotherapy to artificial intelligence - Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016614/ http://dx.doi.org/10.1177/10732748221088825 |
work_keys_str_mv | AT pengzheng photoimmunotherapyanewparadigminsolidtumorimmunotherapy AT lvxiaolan photoimmunotherapyanewparadigminsolidtumorimmunotherapy AT huangshigao photoimmunotherapyanewparadigminsolidtumorimmunotherapy |